HMS
LOE ApproachingNDAOPHTHALMICSUSPENSION
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HMS by AbbVie is clinical pharmacology hms (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Approved for allergic conjunctivitis, vernal conjunctivitis, episcleritis and 1 more indications. First approved in 1969.
Drug data last refreshed 2d ago
Mechanism of Action
CLINICAL PHARMACOLOGY HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation,…
Indications (4)
Worked on HMS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.